
Avenue Therapeutics ATXI
Quartalsbericht 2025-Q3
hinzugefügt 13.11.2025
Avenue Therapeutics Kurzfristige Verbindlichkeiten 2011-2026 | ATXI
Kurzfristige Verbindlichkeiten Jährlich Avenue Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 816 K | 1.2 M | 3.58 M | 509 K | 886 K | 2.12 M | 5.16 M | 2.79 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.16 M | 509 K | 2.13 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Precigen
PGEN
|
37.3 M | $ 3.1 | -0.96 % | $ 758 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 19.57 | 1.77 % | $ 915 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.33 | 0.76 % | $ 339 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
25.6 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
70.6 M | - | - | $ 789 M | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
20.7 M | $ 8.31 | 1.59 % | $ 111 M | ||
|
CRISPR Therapeutics AG
CRSP
|
149 M | $ 47.09 | 1.42 % | $ 4.23 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
6.01 M | $ 4.53 | 5.1 % | $ 868 M | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
CytomX Therapeutics
CTMX
|
46.6 M | $ 4.22 | -0.47 % | $ 582 M | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
6.27 M | - | -5.98 % | $ 34.1 M |